Cerevance reported Phase 3 results for solengepras, an investigational add-on pill for Parkinson’s disease designed to reduce daily “off” time without directly targeting dopamine. The company said the higher dose met the trial’s primary goal, lowering average daily off time versus placebo after 12 weeks. Cerevance also reported improvements on on time and other patient-reported measures, with safety described as generally well tolerated and no serious adverse events in the higher-dose arm. The trial compared placebo with lower and higher once-daily doses in a study of 341 participants. The data set positions solengepras for regulator discussions on potential approval, particularly for patients experiencing motor fluctuations despite levodopa and other therapies.